Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant.
In certain models of allergic airway disease, mast cells facilitate the development of inflammation and airway hyper-responsiveness (AHR). To define the role of the high affinity IgE receptor (FcepsilonRI) in the development of AHR, mice with a disruption of the alpha subunit of the high affinity IgE receptor (FcepsilonRI(-/-)) were exposed on 10 consecutive days to nebulized OVA. Forty-eight hours after the last nebulization, airway responsiveness was monitored by the contractile response of tracheal smooth muscle to electrical field stimulation (EFS). After the 10-day OVA challenge protocol, wild-type mice demonstrated increased responsiveness to EFS, whereas similarly challenged FcepsilonRI(-/-) mice showed a low response to EFS, similar to nonexposed animals. Further, allergen-challenged FcepsilonRI(-/-) mice showed less airway inflammation, goblet cell hyperplasia, and lower levels of IL-13 in lung homogenates compared with the controls. IL-13-deficient mice failed to develop an increased response to EFS or goblet cell hyperplasia after the 10-day OVA challenge. We transferred bone marrow-derived mast cells from wild-type mice to FcepsilonRI(-/-) mice 1 day before initiating the challenge protocol. After the 10-day OVA challenge, recipient FcepsilonRI(-/-) mice demonstrated EFS-induced responses similar to those of challenged wild-type mice. Transferred mast cells could be detected in tracheal preparations. These results show that FcepsilonRI is important for the development of AHR after an aerosolized allergen sensitization protocol and that this effect is mediated through FcepsilonRI on mast cells and production of IL-13 in the lung.
Taube
Christian
C
Division of Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.
Wei
Xudong
X
Swasey
Christina H
CH
Joetham
Anthony
A
Zarini
Simona
S
Lively
Tricia
T
Takeda
Katsuyuki
K
Loader
Joan
J
Miyahara
Nobuaki
N
Kodama
Taku
T
Shultz
Lenny D
LD
Donaldson
Debra D
DD
Hamelmann
Eckard H
EH
Dakhama
Azzeddine
A
Gelfand
Erwin W
EW
D000276:Adjuvants, Immunologic; D019264:Adoptive Transfer; D000336:Aerosols; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology; D016535:Bronchial Hyperreactivity / Q000235:genetics / Q000276:immunology*; D004558:Electric Stimulation; D005260:Female; D020397:Goblet Cells / Q000276:immunology / Q000473:pathology; D006965:Hyperplasia; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007249:Inflammation / Q000235:genetics / Q000473:pathology; D018793:Interleukin-13 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D007970:Leukopenia / Q000235:genetics / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000473:pathology; D008407:Mast Cells / Q000276:immunology* / Q000473:pathology / Q000637:transplantation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D009330:Nebulizers and Vaporizers; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D017455:Receptors, IgE / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D014132:Trachea / Q000166:cytology / Q000276:immunology / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000336:Aerosols; D000485:Allergens; C475664:FCER1A protein, human; D007074:Immunoglobulin G; D018793:Interleukin-13; D017455:Receptors, IgE; D007073:Immunoglobulin E; D010047:Ovalbumin